Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study (Q37380288)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 July 2009

Language	Label	Description	Also known as
English	Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study	scientific article published on 22 July 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Takao Koike

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

Tsutomu Takeuchi

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Nobuyuki Miyasaka

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Kazuhiko Inoue

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Tohru Abe

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

RISING study

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

publication date

22 July 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Modern Rheumatology

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

19

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

478-487

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

Infliximab in active early rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

6 September 2017

The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

28 September 2017

A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

26 June 2018

Smallest detectable difference in radiological progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

26 June 2018

Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

26 June 2018

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

2 September 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

3 December 2018

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

2 September 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759008

2 September 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0195-8

21 January 2018

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2FS10165-009-0195-8

21 January 2018

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic criteria in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19626391

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/S10165-009-0195-8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37380288&oldid=2117958808"